Ozempic Alternatives (2026): FDA-Approved GLP-1s, Cheaper Semaglutide & Non-GLP-1 Options

“Ozempic alternatives” is one of the most-searched GLP-1 brand questions, but the framing usually conflates three distinct goals. Most patients asking about Ozempic alternatives want one of: (1) a different weight-loss-indicated GLP-1, (2) a cheaper or more accessible semaglutide, or (3) a non-GLP-1 weight-loss option. Each goal has different alternatives and different insurance implications. Here is the structured answer for each.

Why are you looking for an Ozempic alternative?

First, what Ozempic is and is not:

• Ozempic is FDA-approved for type 2 diabetes only — glycemic control, plus cardiovascular risk reduction in adults with T2D and established CVD, plus chronic kidney disease risk reduction (FLOW indication added 2025).
• Ozempic is NOT FDA-approved for weight loss alone. Off-label use of Ozempic for weight loss is legal but rarely insurance-covered, because both Cigna CNF 360 and Aetna 2439-C explicitly gate Ozempic behind a documented T2D diagnosis.
• Ozempic and Wegovy contain the same active ingredient (semaglutide), made by the same manufacturer (Novo Nordisk). They are sold under different brand names by FDA-approved indication: Ozempic for diabetes (max 2 mg weekly), Wegovy for chronic weight management (max 2.4 mg weekly).

With those facts in mind, the right Ozempic alternative depends on which problem you're solving. Pick the goal that matches yours and skip to that section.

Goal #1 — A different weight-loss-indicated GLP-1

If you have obesity (BMI ≥ 30) or overweight (BMI ≥ 27 with comorbidity) but NOT type 2 diabetes, you want a weight-loss-indicated GLP-1 that insurance will cover with the right PA submission. The FDA-approved options:

Best for largest weight loss: Zepbound (tirzepatide). SURMOUNT-5 (NEJM 2025, PMID 39891752) showed tirzepatide produced greater mean weight loss than semaglutide in a head-to-head.

Best for oral preference: Foundayo (orforglipron) is the first oral non-peptide GLP-1 FDA-approved for chronic weight management (April 2026). No fasting restrictions like Rybelsus.

Best if cost is the constraint: Wegovy at $299/mo NovoCare standard pen is the cheapest brand-name weight-loss-indicated GLP-1 injection; Foundayo at $149/mo is the cheapest oral.

For deeper comparison see Wegovy vs Mounjaro decision guide, Mounjaro vs Zepbound complete comparison, and brand-name cheat sheet.

Goal #2 — Cheaper or more accessible semaglutide

If your goal is to stay on semaglutide (the active ingredient in Ozempic) but find a cheaper or more accessible path, you have several verified 2026 options:

• NovoCare Pharmacy self-pay — Wegovy standard pen $299/month (verified 2026-05-09; the older $499/month figure is outdated). Wegovy oral pill 1.5/4 mg $149/month through Aug 31, 2026. Wegovy HD 7.2 mg pen $399/month. Ozempic new patient $199/month for first 2 months; $349 standard.
• Costco Member Prescription Program (CMPP) via Sesame — Wegovy and Ozempic at $349/month. New patient $199/month for first 2 months. The first true retailer-discount tier below the manufacturer floor. Membership-gated for the discount; non-members can fill at posted cash price by federal pharmacy access law.
• Sam's Club Plus Pharmacy — oral Wegovy 1.5 mg at $149/month (launched January 2026); Wegovy + Ozempic injection pens at $499/month via the Novo Nordisk Copay Savings Program. Free same-day refrigerated delivery for Plus members.
• GoodRx coupons — Wegovy oral pill 1.5 mg $149/month manufacturer-funded (through April 15, 2026). Wegovy injection pen via GoodRx is ~$1,300+ retail with 9-24% coupon — NOT the cheapest path.
• Manufacturer copay savings card — Wegovy and Ozempic both available at as little as $25/month for commercially insured patients meeting eligibility.
• Compounded semaglutide from licensed 503A pharmacies — typically $99–$300/month. NOTE: the FDA's enforcement-discretion grace period for compounded semaglutide ended February 2025. The regulatory landscape is unsettled. See our compounded semaglutide provider directory for ranked options + each provider's current regulatory standing.

For the full channel-by-channel guide with verbatim 2026 prices, see Wegovy GoodRx + Cash-Pay Coupon & Channel Guide.

Goal #3 — A non-GLP-1 weight-loss option

If you can't tolerate the GI side effects of GLP-1s, can't access them due to insurance, or prefer an oral pill over an injection, the FDA-approved non-GLP-1 anti-obesity medications are:

• Qsymia (phentermine + topiramate ER) — FDA-approved July 2012 for chronic weight management. Daily capsule. Schedule IV controlled (phentermine component). REMS program for fetal toxicity from topiramate. Mean weight loss ~9-11% at 56 weeks (CONQUER + EQUIP trials).
• Contrave (naltrexone + bupropion ER) — FDA-approved September 2014 for chronic weight management. Twice-daily tablet. Boxed warning for suicidality (bupropion component). Mean weight loss ~5-9% at 56 weeks (COR trials).
• Xenical (orlistat 120 mg, prescription) / alli (orlistat 60 mg, OTC) — FDA-approved 1999 (Rx) and 2007 (OTC). Three times daily with meals. Acts locally in the gut to inhibit fat absorption. Modest weight loss (~3-5% at 1 year) and significant GI side effects (oily stools, fecal urgency).

For the deeper evidence comparison of these non-GLP-1 options vs the GLP-1s, see FDA-approved weight loss medications hub and weight loss injections complete guide.

If you have type 2 diabetes

If you're on Ozempic FOR diabetes (not off-label for weight loss) and looking for an alternative, the FDA-approved options for type 2 diabetes glycemic control are:

• Mounjaro (tirzepatide) — once weekly injection. SURPASS-2 (NEJM 2021) showed tirzepatide superior to semaglutide for A1C reduction (down 2.0-2.5% vs 1.8%). Insurance gates Mounjaro behind a metformin step-therapy requirement.
• Trulicity (dulaglutide) — once weekly injection. REWIND trial (Lancet 2019) for cardiovascular risk reduction. Long-acting GLP-1 RA. No generic; Fc fusion biologic on BLA, biosimilar pathway only.
• Rybelsus (oral semaglutide) — daily tablet. Fasted administration with small water volume. Same molecule as Ozempic + Wegovy but oral. Cardiovascular risk-reduction indication added October 2025 (7 + 14 mg only, per SOUL trial).
• Victoza (liraglutide) + generic liraglutide (Hikma, December 2024) — once daily injection. The generic is the FIRST generic GLP-1 RA in the US.
• Byetta + Bydureon BCise (exenatide) — DISCONTINUED by AstraZeneca in October 2024. Generic exenatide (Amneal) FDA-approved November 21, 2024 — a historical reference now.
• Non-GLP-1 type 2 diabetes drugs — metformin (first-line per ADA), SGLT2 inhibitors (Jardiance, Farxiga, Invokana), DPP-4 inhibitors (Januvia, Tradjenta), sulfonylureas, TZDs, insulin. Talk to your endocrinologist about the right combination.

For the full GLP-1 landscape see our GLP-1 complete guide.

Quick decision matrix

• Ozempic but want better weight loss? → Zepbound (tirzepatide for weight management) or Wegovy (same molecule, weight-management indication)
• Ozempic but want cheaper? → Wegovy NovoCare $299/mo; Costco CMPP $349/mo; compounded semaglutide $99-$300/mo (regulatory caveat)
• Ozempic but want oral? → Foundayo (orforglipron) for weight management; Rybelsus (oral semaglutide) for diabetes
• Ozempic but can't tolerate GI side effects? → Try the next-tier-down dose; or switch to Qsymia / Contrave / Xenical (non-GLP-1)
• Ozempic but insurance denied weight-loss coverage? → File appeal with Letter of Medical Necessity per the Aetna PA guide / Cigna PA guide; or use cash-pay path